Cardiologicum Hamburg GbR
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Cardiologicum Hamburg GbR, most studies focus on cardiovascular disease, especially conditions linked to high risk of major events. Research includes atrial fibrillation, heart failure, hypertrophic cardiomyopathy, and atherosclerotic cardiovascular disease, with trials designed to test new treatments, reduce complications, and improve long-term outcomes.
- Testing therapies to lower the risk of stroke, heart attack, and other major cardiovascular events
- Studying treatments for heart failure, including reduced, preserved, and mildly reduced ejection fraction
- Evaluating care for atrial fibrillation and symptomatic hypertrophic cardiomyopathy
Several projects also examine whether newer approaches can improve symptom control and prevent hospitalizations in people already receiving standard care.
Nutritional and Metabolic Diseases
The site also conducts trials in nutritional and metabolic diseases, with a strong emphasis on hypercholesterolemia, hyperlipidaemia, elevated lipoprotein(a), and type 2 diabetes. These studies aim to improve lipid management, lower cardiovascular risk, and explore treatments for people with obesity-related heart conditions.
- Assessing therapies that reduce LDL cholesterol and other blood lipids
- Studying elevated lipoprotein(a) as a driver of cardiovascular risk
- Evaluating treatments for type 2 diabetes alongside heart and blood pressure disease
Research here often combines metabolic care with cardiovascular prevention, reflecting the close connection between cholesterol, diabetes, obesity, and heart disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 therapeutic areas and 15 of 19 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1Amgen Inc.2active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +4 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cardiologicum Hamburg GbR
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 19 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rosuvastatin | 3 | Unknown | 2022-04-08 | 2024-11-10 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.